Company: PRTA
Filing Date: 2025-03-28
Form Type: DEF 14A
Source: 0001559053-25-000017
Chunk: 38

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-03-28
Form: DEF 14A
Chunk 38
---
-class, next-generation subcutaneous antibody for the treatment of Alzheimer’s disease (AD) that targets a key epitope at the N-terminus of amyloid beta (Aβ) with high binding potency. In 2024, Prothena continued enrollment in our ongoing ASCENT clinical trials (reaching approximately 260 patients) and presented posters at the Alzheimer’s Association International Conference (AAIC) and the Clinical Trials on Alzheimer’s Disease conference (CTAD) highlighting the clinical trial design of the Phase 1 ASCENT clinical trials.

◦ BMS-986446 (formerly PRX005), a potential best-in-class antibody for the treatment of AD

that specifically targets a key epitope within the microtubule binding region (MTBR) of tau, a protein implicated in the causal pathophysiology of AD. BMS-986446 is part of the global neuroscience research and development collaboration with Bristol Myers Squibb (BMS). In 2024, BMS continued to enroll the ongoing Phase 2 TargetTau-1 clinical trial in approximately 475 patients with early Alzheimer’s disease and presented the design of the ongoing Phase 2 TargetTau-1 clinical trial in a poster presentation at AAIC and an oral encore presentation at CTAD.

◦ Prasinezumab, a potential first-in-class antibody, for the treatment for Parkinson’s disease (PD), that is designed to target key epitopes within the C-terminus of alpha-synuclein and is the focus of the worldwide collaboration with Roche. In 2024, Roche reported results from the Phase 2b PADOVA clinical trial in patients with early-stage Parkinson’s disease missed the primary endpoint but showed a numerical delay in motor progression and positive trends on multiple secondary and exploratory endpoints suggesting possible clinical benefit. Roche announced that they will continue to evaluate the data and work together with health authorities to determine next steps.

◦ PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target, is part of the global neuroscience research and development collaboration with BMS. In 2024, Bristol Myers Squibb obtained the exclusive global license for PRX019 for $80 million; and Prothena initiated a Phase 1 first-in-human clinical trial to evaluate the safety, tolerability, immunogenicity, and pharmaco-kinetics of single ascending and multiple doses in healthy adults.

• We Made Significant Advances in our Rare Peripheral Amyloid Diseases Portfolio.

◦ Birtamimab